Chengyan Dong

1.1k total citations
30 papers, 881 citations indexed

About

Chengyan Dong is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Chengyan Dong has authored 30 papers receiving a total of 881 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Chengyan Dong's work include Radiopharmaceutical Chemistry and Applications (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cell Adhesion Molecules Research (6 papers). Chengyan Dong is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cell Adhesion Molecules Research (6 papers). Chengyan Dong collaborates with scholars based in China, United States and France. Chengyan Dong's co-authors include Fan Wang, Zhaofei Liu, Bing Jia, Mingyuan Gao, Kan Liu, Ruirui Qiao, Fang Fang, Yi Hou, Chunyan Liu and Hao Lei and has published in prestigious journals such as ACS Nano, Analytical Chemistry and Hepatology.

In The Last Decade

Chengyan Dong

29 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chengyan Dong China 18 324 230 212 200 173 30 881
Louiza Loizou Sweden 14 280 0.9× 231 1.0× 132 0.6× 245 1.2× 145 0.8× 23 952
Emeline J. Ribot France 18 215 0.7× 210 0.9× 112 0.5× 203 1.0× 205 1.2× 53 871
Brooke Helfer United States 10 180 0.6× 279 1.2× 140 0.7× 148 0.7× 107 0.6× 13 697
Ann‐Marie Chacko United States 18 188 0.6× 299 1.3× 92 0.4× 221 1.1× 173 1.0× 47 1.0k
Deepak K. Kadayakkara United States 12 278 0.9× 161 0.7× 302 1.4× 187 0.9× 139 0.8× 20 857
Jiaji Mao China 19 244 0.8× 252 1.1× 171 0.8× 415 2.1× 75 0.4× 29 1.0k
Joseph J. Grudzinski United States 14 348 1.1× 174 0.8× 136 0.6× 329 1.6× 195 1.1× 44 924
Jessica L. Crisp United States 15 226 0.7× 430 1.9× 88 0.4× 296 1.5× 170 1.0× 18 1.1k
Xinhui Su China 23 294 0.9× 408 1.8× 234 1.1× 414 2.1× 205 1.2× 76 1.3k
A. Bogdanova United States 10 409 1.3× 356 1.5× 221 1.0× 266 1.3× 70 0.4× 18 1.2k

Countries citing papers authored by Chengyan Dong

Since Specialization
Citations

This map shows the geographic impact of Chengyan Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengyan Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengyan Dong more than expected).

Fields of papers citing papers by Chengyan Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengyan Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengyan Dong. The network helps show where Chengyan Dong may publish in the future.

Co-authorship network of co-authors of Chengyan Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Chengyan Dong. A scholar is included among the top collaborators of Chengyan Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengyan Dong. Chengyan Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Xuezhu, Jingnan Wang, Chengyan Dong, et al.. (2023). Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents. Journal of Hepatocellular Carcinoma. Volume 10. 587–598. 5 indexed citations
3.
Xing, Haiqun, Wenjia Zhu, Chengyan Dong, et al.. (2022). Dynamic PET/CT scan of 68Ga-FAPI-04 for the optimal acquisition time in suspected malignant hepatic cancer patients. Abdominal Radiology. 48(3). 895–901. 7 indexed citations
4.
Li, Dengfeng, Chengyan Dong, Xiaohong Ma, & Xinming Zhao. (2021). Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model. Cancer Imaging. 21(1). 44–44. 7 indexed citations
5.
Jin, Xiaona, Chengyan Dong, Ximin Shi, et al.. (2021). Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In Vivo. Frontiers in Oncology. 11. 792431–792431. 47 indexed citations
6.
Sun, Haiyang, Bixiao Cui, Hongwei Yang, et al.. (2021). The Relationship Among Glucose Metabolism, Cerebral Blood Flow, and Functional Activity: a Hybrid PET/fMRI Study. Molecular Neurobiology. 58(6). 2862–2873. 18 indexed citations
7.
Song, Shuangshuang, Leiming Wang, Hongwei Yang, et al.. (2020). Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status. European Radiology. 31(6). 4087–4096. 23 indexed citations
8.
9.
Song, Shuangshuang, Ye Cheng, Leiming Wang, et al.. (2020). Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. European Journal of Nuclear Medicine and Molecular Imaging. 47(6). 1458–1467. 61 indexed citations
10.
Wu, Yue, Liqiang Li, Zihua Wang, et al.. (2020). Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. European Journal of Nuclear Medicine and Molecular Imaging. 47(11). 2613–2623. 21 indexed citations
11.
Gao, Shi, Bing Jia, Guo‐Kai Feng, et al.. (2020). First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Signal Transduction and Targeted Therapy. 5(1). 147–147. 10 indexed citations
12.
Chen, Xi, Xin Zhang, Ming Du, et al.. (2019). In vivo preclinical PET/CT imaging of carbon-11-labeled aminoglycerol probe for the diagnosis of liver fibrosis. Annals of Nuclear Medicine. 33(11). 806–812. 4 indexed citations
13.
Li, Liqiang, Yue Wu, Zihua Wang, et al.. (2017). SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models. Journal of Nuclear Medicine. 58(5). 821–826. 64 indexed citations
14.
Dong, Chengyan, Sujuan Yang, Jiyun Shi, et al.. (2016). SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System. Scientific Reports. 6(1). 18905–18905. 22 indexed citations
15.
Zhang, Xin, Meinan Yao, Muhua Chen, et al.. (2016). Hyaluronic Acid-Coated Silver Nanoparticles As a Nanoplatform for in Vivo Imaging Applications. ACS Applied Materials & Interfaces. 8(39). 25650–25653. 38 indexed citations
16.
Wang, Zihua, Weizhi Wang, Xiangli Bu, et al.. (2015). Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor. Analytical Chemistry. 87(16). 8367–8372. 49 indexed citations
17.
Dong, Chengyan, Zhaofei Liu, & Fan Wang. (2015). Radioligand saturation binding for quantitative analysis of ligand-receptor interactions. Biophysics Reports. 1(3). 148–155. 27 indexed citations
18.
Shi, Jiyun, Di Fan, Chengyan Dong, et al.. (2014). Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar. Theranostics. 4(3). 256–266. 30 indexed citations
19.
20.
Li, Yang, Zhaofei Liu, Chengyan Dong, et al.. (2012). Noninvasive Detection of Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Teratoma with an Integrin-Targeting Agent 99mTc-3PRGD2. Molecular Imaging and Biology. 15(1). 58–67. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louiza Loizou Breakdown of academic impact, for papers by Emeline J. Ribot Breakdown of academic impact, for papers by Brooke Helfer Breakdown of academic impact, for papers by Ann‐Marie Chacko Breakdown of academic impact, for papers by Deepak K. Kadayakkara Breakdown of academic impact, for papers by Jiaji Mao Breakdown of academic impact, for papers by Joseph J. Grudzinski Breakdown of academic impact, for papers by Jessica L. Crisp Breakdown of academic impact, for papers by Xinhui Su Breakdown of academic impact, for papers by A. Bogdanova
Rankless by CCL
2026